GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma — Stella

Home/Glioblastoma Multiforme of Brain/

View on ClinicalTrials.gov

Recruiting

Back to Glioblastoma Multiforme of Brain trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Baylor St. Luke's Medical Center, Houston, Texas

Key details

Phase

Early testing

Sponsor

Baylor College of Medicine

Collaborators

Center for Cell and Gene Therapy, Baylor College of Medicine, Baylor St. Luke's Medical Center

Enrollment target

~27 participants

Started

October 2025

Primary completion

December 2029

Age range

21 Years – 70 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.